Pharma BD Deal Intelligence
Boehringer Ingelheim's $1.5B acquisition of NBE Therapeutics for breast and lung cancer treatments delivered a bust—an outcome score far below its initial critic reception, signaling the deal's pipeline assets failed to translate into the anticipated commercial or clinical progress.
Boehringer Ingelheim acquired NBE Therapeutics for $1.5B for breast and lung cancer treatments.
Acquisition agreement with Boehringer Ingelheim for NBE-Therapeutics first major biotech exit for PPF Group.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Boehringer Ingelheim acquired NBE Therapeutics for $1.5B for breast and lung cancer treatments.
510K US cases/yr · $65.0B Global BC + LC Combined (2024)
BI acquired NBE Therapeutics for $1.5B for iADC (immune-stimulating ADC) platform targeting breast and lung cancers.
AZ/Daiichi (Enhertu $5B+), Pfizer/Seagen ($43B acquisition), Gilead (Trodelvy). ADC M&A is most active oncology area.
Boehringer Ingelheim completed $1.5B acquisition of NBE Therapeutics, gaining next-gen ADC platform using novel payload and linker technology.
NBE ADC technology integrated into BI oncology pipeline with multiple candidates in preclinical and early clinical development.
NBE ADC platform being applied across BI oncology pipeline. No approved products yet. $1.5B is long-term R&D bet on ADC technology.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Boehringer Ingelheim GmbH / NBE Therapeutics (this deal) | 2020 | $1.5B | 28 |
| Boehringer Ingelheim GmbH / Amgen Inc. (Fremont manufacturing facility) | 2011 | — | 77 |
| Boehringer Ingelheim GmbH / AMAL Therapeutics SA | 2019 | $366M | — |
| Boehringer Ingelheim GmbH / Bridge Biotherapeutics, Inc. | 2019 | $1.2B | — |
| Boehringer Ingelheim GmbH / NBE-Therapeutics AG | 2020 | $1.4B | — |
| Boehringer Ingelheim GmbH / Yuhan Corporation | 2019 | $870M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
← Browse all deals · How we score deals
More: 2020 deals · Boehringer Ingelheim GmbH deals · Oncology deals